nach oben

Erschienen in:

14.11.2022 | Functional Neuroradiology

Regional cortical hypoperfusion and atrophy correlate with striatal dopaminergic loss in Parkinson’s disease: a study using arterial spin labeling MR perfusion

verfasst von: Yuki Kitazaki, Masamichi Ikawa, Tomohisa Yamaguchi, Soichi Enomoto, Norimichi Shirafuji, Osamu Yamamura, Tetsuya Tsujikawa, Hidehiko Okazawa, Hirohiko Kimura, Yasunari Nakamoto, Tadanori Hamano

Erschienen in: Neuroradiology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the relationship of the striatal dopamine transporter density to changes in the gray matter (GM) volume and cerebral perfusion in patients with Parkinson’s disease (PD).

Methods

We evaluated the regional cerebral blood flow (CBF) and GM volume, concurrently measured using arterial spin labeling and T1-weighted magnetic resonance imaging, respectively, as well as the striatal specific binding ratio (SBR) in ¹²³I-N-ω-fluoropropyl-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (¹²³I-FP-CIT) single-photon emission computed tomography in 30 non-demented patients with PD (15 men and 15 women; mean age, 67.2 ± 8.8 years; mean Hoehn–Yahr stage, 2.2 ± 0.9). Voxel-wise regression analyses using statistical parametric mapping (SPM) were performed to explore the brain regions that showed correlations of the striatal SBR to the GM volume and CBF, respectively, with a height threshold of p < 0.0005 at the voxel level and p < 0.05 family-wise error-corrected at the cluster level.

Results

SPM analysis showed a significant positive correlation between the SBR and GM volume in the inferior frontal gyrus (IFG). Whereas, a positive correlation between the SBR and CBF was widely found in the frontotemporal and parietotemporal regions, including the IFG. Notably, the opercular part of the IFG showed significant correlations in both SPM analyses of the GM volume (r² = 0.90, p < 0.0001) and CBF (r² = 0.88, p < 0.0001).

Conclusion

The voxel-wise analyses revealed the brain regions, mainly the IFG, that showed hypoperfusion and atrophy related to dopaminergic loss, which suggests that the progression of dopaminergic neurodegeneration leads to regional cortical dysfunction in PD.

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-XCrossRef

Rajput AH, Voll A, Rajput ML et al (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73:206–212. https://doi.org/10.1212/WNL.0b013e3181ae7af1CrossRef

Fereshtehnejad SM, Romenets SR, Anang JB et al (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873. https://doi.org/10.1001/jamaneurol.2015.0703CrossRef

De Pablo-Fernández E, Lees AJ, Holton JL et al (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76:470–479. https://doi.org/10.1001/jamaneurol.2018.4377CrossRef

Ciliax BJ, Heilman C, Demchyshyn LL et al (1995) The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15:1714–1723. https://doi.org/10.1523/jneurosci.15-03-01714.1995CrossRef

Booij J, Tissingh G, Boer GJ et al (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140. https://doi.org/10.1136/jnnp.62.2.133CrossRef

Kraemmer J, Kovacs GG, Perju-Dumbrava L et al (2014) Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29:1767–1773. https://doi.org/10.1002/mds.25975CrossRef

Nagano-Saito A, Washimi Y, Arahata Y et al (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64:224–229. https://doi.org/10.1212/01.WNL.0000149510.41793.50CrossRef

Nishio Y, Hirayama K, Takeda A et al (2010) Corticolimbic gray matter loss in Parkinson’s disease without dementia. Eur J Neurol 17:1090–1097. https://doi.org/10.1111/j.1468-1331.2010.02980.xCrossRef

10.

Guimarães RP, Santos MCA, Dagher A et al (2017) Pattern of reduced functional connectivity and structural abnormalities in Parkinson’s disease: an exploratory study. Front Neurol 7:1–9. https://doi.org/10.3389/fneur.2016.00243CrossRef

11.

Eckert T, Van Laere K, Tang C et al (2007) Quantification of Parkinson’s disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 34:496–501. https://doi.org/10.1007/s00259-006-0261-9CrossRef

12.

Huang C, Mattis P, Tang C et al (2007) Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage 34:714–723. https://doi.org/10.1016/j.neuroimage.2006.09.003CrossRef

13.

Maekawa T, Sato N, Ota M et al (2017) Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson’s disease. Jpn J Radiol 35:755–759. https://doi.org/10.1007/s11604-017-0694-zCrossRef

14.

Choi H, Cheon GJ, Kim HJ et al (2016) Gray matter correlates of dopaminergic degeneration in Parkinson’s disease: a hybrid PET/MR study using 18F-FP-CIT. Hum Brain Mapp 37:1710–1721. https://doi.org/10.1002/hbm.23130CrossRef

15.

Nobili F, Arnaldi D, Campus C et al (2011) Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging 38:2209–2218. https://doi.org/10.1007/s00259-011-1874-1CrossRef

16.

Paschali A, Messinis L, Kargiotis O et al (2010) SPECT neuroimaging and neuropsychological functions in different stages of Parkinson’s disease. Eur J Nucl Med Mol Imaging 37:1128–1140. https://doi.org/10.1007/s00259-010-1381-9CrossRef

17.

Kimura H, Kado H, Koshimoto Y et al (2005) Multislice continuous arterial spin-labeled perfusion MRI in patients with chronic occlusive cerebrovascular disease: a correlative study with CO 2 PET validation. J Magn Reson Imaging 22:189–198. https://doi.org/10.1002/jmri.20382CrossRef

18.

Ikawa M, Kimura H, Kitazaki Y et al (2018) Arterial spin labeling MR imaging for the clinical detection of cerebellar hypoperfusion in patients with spinocerebellar degeneration. J Neurol Sci 394:58–62. https://doi.org/10.1016/j.jns.2018.09.007CrossRef

19.

Syrimi ZJ, Vojtisek L, Eliasova I et al (2017) Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson’s disease. J Neural Transm 124:551–557. https://doi.org/10.1007/s00702-017-1703-1CrossRef

20.

Kamagata K, Motoi Y, Hori M et al (2011) Posterior hypoperfusion in parkinson’s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 33:803–807. https://doi.org/10.1002/jmri.22515CrossRef

21.

Fernández-Seara MA, Mengual E, Vidorreta M et al (2012) Cortical hypoperfusion in Parkinson’s disease assessed using arterial spin labeled perfusion MRI. Neuroimage 59:2743–2750. https://doi.org/10.1016/j.neuroimage.2011.10.033CrossRef

22.

Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424CrossRef

23.

Apostolova I, Taleb DS, Lipp A et al (2017) Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain Parkinsonian syndrome. Clin Nucl Med 42:589–594. https://doi.org/10.1097/RLU.0000000000001696CrossRef

24.

Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429CrossRef

25.

Rahman MGM, Islam MM, Tsujikawa T et al (2019) Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis. Ann Nucl Med 33:14–21. https://doi.org/10.1007/s12149-018-1297-1CrossRef

26.

Rahman MGM, Islam MM, Tsujikawa T, Okazawa H (2020) A novel automatic approach for calculation of the specific binding ratio in [I-123]FP-CIT SPECT. Diagnostics 10:1–11. https://doi.org/10.3390/diagnostics10050289CrossRef

27.

Dai W, Garcia D, De Bazelaire C, Alsop DC (2008) Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 60:1488–1497. https://doi.org/10.1002/mrm.21790CrossRef

28.

Tsujikawa T, Yoneda M, Shimizu Y et al (2010) Pathophysiologic evaluation of MELAS strokes by serially quantified MRS and CASL perfusion images. Brain Dev 32:143–149. https://doi.org/10.1016/j.braindev.2008.12.003CrossRef

29.

Ikawa M, Yoneda M, Muramatsu T et al (2013) Detection of preclinically latent hyperperfusion due to stroke-like episodes by arterial spin-labeling perfusion MRI in MELAS patients. Mitochondrion 13:676–680. https://doi.org/10.1016/j.mito.2013.09.007CrossRef

30.

Thomas DL, Lythgoe MF, van de Weerd L et al (2006) Regional variation of cerebral blood flow and arterial transit time in normal and hyperfused rat brain measured using continuous arterial spin labelling MRI. J Cereb Blood Flow Metab 26:274–282. https://doi.org/10.1038/sj.jcbfm.9600185CrossRef

31.

Herscovitch P, Raichle ME, Kilbourn MR et al (1987) Positron emission tomographic measurement of cerebral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J Cereb Blood Flow Metab 7:527–542. https://doi.org/10.1038/jcbfm.1987.102CrossRef

32.

Alsop DC, Detre JA, Golay X et al (2015) Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 73:102–116. https://doi.org/10.1002/mrm.25197CrossRef

33.

Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007CrossRef

34.

Isaias IU, Benti R, Cilia R et al (2007) [123I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor vs. akinetic-rigid onset. NeuroReport 18:1499–1502. https://doi.org/10.1097/WNR.0b013e3282ef69f9CrossRef

35.

Aron AR, Fletcher PC, Bullmore ET et al (2003) Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 6:115–116. https://doi.org/10.1038/nn1003CrossRef

36.

Donzuso G, Monastero R, Cicero CE et al (2021) Neuroanatomical changes in early Parkinson’s disease with mild cognitive impairment: a VBM study; the Parkinson’s Disease Cognitive Impairment Study (PaCoS). Neurol Sci 42:3723–3731. https://doi.org/10.1007/s10072-020-05034-9CrossRef

37.

Gama RL, Bruin VMS, Távora DGF et al (2014) Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn 87:97–103. https://doi.org/10.1016/j.bandc.2014.03.011CrossRef

38.

Matsui H, Nishinaka K, Oda M et al (2006) Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord 21:1169–1174. https://doi.org/10.1002/mds.20923CrossRef

39.

Han L, Lu J, Tang Y et al (2021) Dopaminergic and metabolic correlations with cognitive domains in non-demented Parkinson’s disease. Front Aging Neurosci 13:1–10. https://doi.org/10.3389/fnagi.2021.627356CrossRef

40.

Ivanidze J, Skafida M, Pandya S et al (2020) Molecular imaging of striatal dopaminergic neuronal loss and the neurovascular unit in Parkinson disease. Front Neurosci 14:1–9. https://doi.org/10.3389/fnins.2020.528809CrossRef

Titel: Regional cortical hypoperfusion and atrophy correlate with striatal dopaminergic loss in Parkinson’s disease: a study using arterial spin labeling MR perfusion
verfasst von: Yuki Kitazaki
Masamichi Ikawa
Tomohisa Yamaguchi
Soichi Enomoto
Norimichi Shirafuji
Osamu Yamamura
Tetsuya Tsujikawa
Hidehiko Okazawa
Hirohiko Kimura
Yasunari Nakamoto
Tadanori Hamano
Publikationsdatum: 14.11.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Neuroradiology / Ausgabe 3/2023
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-022-03085-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Altered functional connectivity within and between resting-state networks in patients with vestibular migraine

Evaluation of the cerebrovascular reactivity in patients with Moyamoya Angiopathy by use of breath-hold fMRI: investigation of voxel-wise hemodynamic delay correction in comparison to [15O]water PET

32nd year Turkish Society of Neuroradiology congress with International Participation

Prognostic value of pretreatment diffusion-weighted imaging score for acute basilar artery occlusion with successful endovascular recanalization

Contrast-induced encephalopathy following endovascular treatment for intracranial aneurysms—risk factors analysis and clinical strategy